Residual risk in statin-treated patients: Future therapeutic options

Current Cardiology Reports

Volumn 9, Issue 6, 2007, Pages 499-505

  Campbell, Catherine Y ^b   Rivera, Juan J ^b   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COLESEVELAM; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; RESIN; ROSUVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DIET THERAPY; DRUG COST; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DYSPEPSIA; EXERCISE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART EJECTION FRACTION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIVER FAILURE; LIVER TOXICITY; METABOLIC SYNDROME X; MONOTHERAPY; MORBIDITY; MORTALITY; MYALGIA; MYOSITIS; PATIENT COMPLIANCE; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SMOKING CESSATION; WEIGHT CONTROL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK;

EID: 36049026764     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02938395     Document Type: Review

References (38)

1. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
2. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
3. Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
4. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
5. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
6. Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
7. LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998, 339:1349-1357.
8. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
9. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
10. Nissen SE, Nicholls SJ, Sipahi I, et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565.
11. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
12. Grundy SM, Cleeman JI, Metz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
13. Briel M, Schwartz GG, Thompson PL, et al.: Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006, 295:2046-2056.
14. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
15. Taylor AJ, Sullenberger LE, Lee HJ, et al.: Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
16. Deedwania P, Barter P, Carmena R, et al.: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006, 368:919-928.
17. Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. New Engl J Med 2005, 352:20-28.
18. Michos ED, Ardehali R, Blumenthal RS, et al.: Aspirin and clopidogrel resistance. Mayo Clin Proc 2006, 81:518-526.
19. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38.
20. Ridker PM; JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003, 108:2292-2297.
21. Assmann G, Benecke H, Neiss A, et al.: Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy: results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rebabil 2006, 13:776-783.
22. Ansell BJ, Fonarow GC, Maki KC, et al.: Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J 2006, 152:976-981.
23. Bays HE, Davidson M, Jones MR, Abby SL: Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006, 97:1198-1205.
24. Pearson TA, Denke MA, McBride PE, et al.: Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc 2006; 81:1177-1185.
25. Castro Cabezas M, de Vries JH, Van Oostrom AJ, et al.: Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. J Am Diet Assoc 2006, 106:1564-1569.
26. Blair SN, Capuzzi DM, Gottlieb SO, et al.: Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000, 86:46-52.
27. Gordon DJ, Probstfield JL, Garrison RJ, et al.: High-density lipoprotein and cardiovascular disease: four prospective American studies. Circulation 1995, 79:8-15.
28. King AC, Haskell WL, Young DR, et al.: Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation 1995, 91:2596-2604.
29. Maeda K, Noguchi Y, Fukui T: The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 2003, 37:283-290.
30. Dattilo AM, Krisetherton PM: Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992, 56:320-328.
31. Ellison RC, Zhang YQ, Qureshi MM, et al.: Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J 2004, 147:529-535.
32. Gerasimova E, Perova N, Ozerova I, et al.: The effect of dietary n-3 polyunsaturated fatty acids on HDL cholesterol in Chukot residents vs Muscovites. Lipids 1991, 26:261-265.
33. Alderman JD, Pasternak RC, Sacks FM, et al.: Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high-density lipoprotein cholesterol and the cholesterol to high-density lipoprotein ratio. Am J Cardiol 1989, 64:725-729.
34. Prueksaritanont T, Zhao JJ, Ma B, et al.: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002, 301:1042-1051.
35. McKenney JM, Davidson MH, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006, 48:1782-1790.
36. Kastelein JJ, van Leuven SI, Burgess L, et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356:1620-1630.
37. Nissen SE, Tardif JC, Nicholls SJ, et al.: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304-1316.
38. Bots ML, Visseren FL, Evans GW, et al.: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370:153-160.